TY - JOUR
T1 - Potentiating action of MKC-242, a selective 5-HT(1A) receptor agonist, on the photic entrainment of the circadian activity rhythm in hamsters
AU - Moriya, T.
AU - Yoshinobu, Y.
AU - Ikeda, M.
AU - Yokota, S.
AU - Akiyama, M.
AU - Shibata, S.
PY - 1998
Y1 - 1998
N2 - 1. Serotonergic projections from the midbrain raphe nuclei to the suprachiasmatic nuclei (SCN) are known to regulate the photic entrainment of circadian clocks. However, it is not known which 5-hydroxytryptamine (5-HT) receptor subtypes are involved in the circadian regulation. In order to verify the role of 5-HT(1A) receptors, we examined the effects of 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]-propoxy}-1,3-benzodioxole HCl (MKC-242), a selective 5-HT(1A) receptor agonist, on photic entrainment of wheel-running circadian rhythms of hamsters. 2. MKC-242 (3 mg kg-1, i.p.) significantly accelerated the re-entrainment of wheel-running rhythms to a new 8 h delayed or advanced light-dark cycle. 3. MKC-242 (3 mg kg-1, i.p.) also potentiated the phase advance of the wheel-running rhythm produced by low (5 lux) or high (60 lux) intensity light pulses. In contrast, 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) (5 mg kg-1, i.p.), a well known 5-HT(1A)/5-HT7 receptor agonist, only suppressed low intensity (5 lux) light-induced phase advances. 4. The potentiating actions of MKC-242 on light pulse-induced phase advances were observed even when injected 20 or 60 min after the light exposure. 5. The potentiating action of MKC-242 was antagonized by WAY100635, a selective S-HT(1A) receptor blocker, but not by ritanserin, a 5-HT2/5-HT7 receptor blocker, indicating that MKC-242 is activating 5-HT(1A) receptors. 6. Light pulse-induced c-fos expression in the SCN and the intergeniculate leaflet (IGL) were unaffected by MKC-242 (3 mg kg-1, i.p.). 7. HPLC analysis demonstrated that MKC-242 (3 mg kg-1, i.p.) decreased the 5-HIAA content in the SCN. 8. The present results suggest that presynaptic 5-HT(1A) receptor activation may be involved in the potentiation of photic entrainment by MKC-242 in hamsters.
AB - 1. Serotonergic projections from the midbrain raphe nuclei to the suprachiasmatic nuclei (SCN) are known to regulate the photic entrainment of circadian clocks. However, it is not known which 5-hydroxytryptamine (5-HT) receptor subtypes are involved in the circadian regulation. In order to verify the role of 5-HT(1A) receptors, we examined the effects of 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]-propoxy}-1,3-benzodioxole HCl (MKC-242), a selective 5-HT(1A) receptor agonist, on photic entrainment of wheel-running circadian rhythms of hamsters. 2. MKC-242 (3 mg kg-1, i.p.) significantly accelerated the re-entrainment of wheel-running rhythms to a new 8 h delayed or advanced light-dark cycle. 3. MKC-242 (3 mg kg-1, i.p.) also potentiated the phase advance of the wheel-running rhythm produced by low (5 lux) or high (60 lux) intensity light pulses. In contrast, 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) (5 mg kg-1, i.p.), a well known 5-HT(1A)/5-HT7 receptor agonist, only suppressed low intensity (5 lux) light-induced phase advances. 4. The potentiating actions of MKC-242 on light pulse-induced phase advances were observed even when injected 20 or 60 min after the light exposure. 5. The potentiating action of MKC-242 was antagonized by WAY100635, a selective S-HT(1A) receptor blocker, but not by ritanserin, a 5-HT2/5-HT7 receptor blocker, indicating that MKC-242 is activating 5-HT(1A) receptors. 6. Light pulse-induced c-fos expression in the SCN and the intergeniculate leaflet (IGL) were unaffected by MKC-242 (3 mg kg-1, i.p.). 7. HPLC analysis demonstrated that MKC-242 (3 mg kg-1, i.p.) decreased the 5-HIAA content in the SCN. 8. The present results suggest that presynaptic 5-HT(1A) receptor activation may be involved in the potentiation of photic entrainment by MKC-242 in hamsters.
KW - 5-HT(1A) receptor
KW - 5-Hydroxytryptamine (5-HT)
KW - Circadian rhythm
KW - Light-entrainment
UR - http://www.scopus.com/inward/record.url?scp=0031773912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031773912&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0702176
DO - 10.1038/sj.bjp.0702176
M3 - Article
C2 - 9863658
AN - SCOPUS:0031773912
SN - 0007-1188
VL - 125
SP - 1281
EP - 1287
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 6
ER -